|
|
|
|
|
|
Sponsored by: |
Organisation for Oncology and Translational Research |
Information provided by: | Organisation for Oncology and Translational Research |
ClinicalTrials.gov Identifier: | NCT00135018 |
This study will investigate whether cyclooxygenase inhibition with celecoxib will add any benefit to preoperative chemotherapy alone for breast cancer patients.
Condition | Intervention | Phase |
Breast Cancer |
Drug: celecoxib and chemotherapy |
Phase II |
Genetics Home Reference related topics: | breast cancer |
MedlinePlus related topics: | Breast Cancer Cancer |
ChemIDplus related topics: | Celecoxib 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Phase II Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patients with serious cardiac illness or medical conditions including, but not confined to:
Contact: Louis WC Chow | (852)2861 0286 | lwcchow@unimed.hk |
Hong Kong | |||||
UNIMED Medical Institute | Recruiting | ||||
Hong Kong, Hong Kong | |||||
Contact: Louis WC Chow (852)2861 0286 lwcchow@unimed.hk | |||||
Principal Investigator: Louis WC Chow |
Organisation for Oncology and Translational Research |
Principal Investigator: | Louis WC Chow | UNIMED Medical Institute |
Study ID Numbers: | FEC-DOC-CXB-A3 |
First Received: | August 24, 2005 |
Last Updated: | April 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00135018 |
Health Authority: | Hong Kong: Department of Health |
|
|
|